Insights from Privotal Trials for Aflibercept (8 mg) in RVO

This segment explores emerging data on aflibercept 8 mg for retinal vein occlusion (RVO) and the evolving understanding of disease chronicity under anti-VEGF therapy. The panelists discuss the pivotal QUASAR trial, which uniquely combined CRVO and BRVO populations and demonstrated that aflibercept 8 mg achieved comparable visual and anatomic outcomes to 2 mg monthly dosing—with the potential for extended 8–12 week intervals after loading. They note that only about 6–7% of patients required monthly treatment at 36 weeks, highlighting promising durability even in severe VEGF-driven disease. Expert faculty reflect on the persistent treatment burden of RVO, emphasizing that many patients—especially older ones—require lifelong injections. The panel also examines a thought-provoking observation: collateral vessel formation appears less frequent in the anti-VEGF era. They debate whether continuous VEGF suppression may delay natural vascular remodeling, balancing vision preservation with long-term retinal adaptation